Published • loading... • Updated
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
The once-daily pill produced nausea and other side effects similar to rival oral GLP-1 drugs, AstraZeneca said.
- AstraZeneca reported phase 2 results in the Lancet showing its once-daily oral GLP-1 drug produced an average 10.5% body-weight reduction after 26 weeks in two studies involving more than 700 people.
- Demand for weight-loss treatments has surged in recent years, fueling a competitive race among pharmaceutical companies to produce tablet versions of popular injectable GLP-1 agonists for greater patient convenience.
- Researchers found the pill improved blood sugar levels, with side effects like nausea similar to other drugs; unlike rival treatments, elecoglipron can be taken at any time of day without food restrictions.
- AstraZeneca faces stiff competition from Novo Nordisk and Eli Lilly; Novo Nordisk's Wegovy achieved 13.6% reduction over 64 weeks, while Eli Lilly's Mounjaro delivered 11.2% reduction over 72 weeks.
- Cambridge University expert Marie Spreckley noted substantial improvements in weight and glycaemic control, though she explained, "Larger and longer phase 3 trials will therefore be needed to confirm the durability of these effects, establish longer-term safety and tolerability.
Insights by Ground AI
13 Articles
13 Articles
Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes
(MedPage Today) -- NEW ORLEANS -- Treatment with investigational elecoglipron led to weight loss in people with obesity and improved glucose control in those with type 2 diabetes, a pair of global phase II randomized trials showed. In the dose...
·New York, United States
Read Full Article
This pill developed by AstraZeneca has a weight loss comparable to other oral versions of its competitors, according to a study published on 8 June. The results must be confirmed by wider tests.
·Paris, France
Read Full Article
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources13
Leaning Left2Leaning Right0Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
